NO20076566L - Ny fremgangsmate for behandling av hyperlipidemi - Google Patents

Ny fremgangsmate for behandling av hyperlipidemi

Info

Publication number
NO20076566L
NO20076566L NO20076566A NO20076566A NO20076566L NO 20076566 L NO20076566 L NO 20076566L NO 20076566 A NO20076566 A NO 20076566A NO 20076566 A NO20076566 A NO 20076566A NO 20076566 L NO20076566 L NO 20076566L
Authority
NO
Norway
Prior art keywords
hyperlipidemia
treatment
new method
hmg
preventing
Prior art date
Application number
NO20076566A
Other languages
English (en)
Inventor
Tomoyuki Nishimoto
Ryuichi Tozawa
Takeo Wada
Eiichiro Ishikawa
Toshiya Nishi
Hiroko Yamakawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20076566L publication Critical patent/NO20076566L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En farmasøytisk sammensetning anvendelig for å hindre og/eller behandle hyperlipidemi som innbefatter å kombinere en effektiv mengde skvalensyntaseinhibitor og HMG-CoA-reduktaseinhibitor er tilveiebrakt.
NO20076566A 2005-06-01 2007-12-19 Ny fremgangsmate for behandling av hyperlipidemi NO20076566L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68587105P 2005-06-01 2005-06-01
US72832905P 2005-10-20 2005-10-20
PCT/JP2006/311362 WO2006129859A2 (en) 2005-06-01 2006-05-31 Combinations of a squalene synthase inhibitor and a hmg-coa reductase inhibitor for treating hyperlipidemia

Publications (1)

Publication Number Publication Date
NO20076566L true NO20076566L (no) 2008-02-22

Family

ID=36699172

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076566A NO20076566L (no) 2005-06-01 2007-12-19 Ny fremgangsmate for behandling av hyperlipidemi

Country Status (17)

Country Link
US (1) US20090209510A1 (no)
EP (1) EP1962832A2 (no)
JP (1) JP2008542191A (no)
KR (1) KR20080012916A (no)
AR (1) AR054368A1 (no)
AU (1) AU2006253255A1 (no)
BR (1) BRPI0610484A2 (no)
CA (1) CA2609784A1 (no)
CR (1) CR9521A (no)
IL (1) IL187207A0 (no)
MA (1) MA29531B1 (no)
MX (1) MX2007014730A (no)
NO (1) NO20076566L (no)
PE (1) PE20070603A1 (no)
RU (1) RU2007149337A (no)
TW (1) TW200714280A (no)
WO (1) WO2006129859A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
EP2229939A4 (en) * 2008-01-10 2011-04-27 Takeda Pharmaceutical CAPSULE FORMULATION
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
EP2694981A1 (en) 2011-04-08 2014-02-12 Zora Biosciences OY Biomarkers for sensitive detection of statin-induced muscle toxicity
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI760067B (zh) * 2020-08-13 2022-04-01 友霖生技醫藥股份有限公司 固態口服醫藥組成物
US11833133B2 (en) 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
AU5140993A (en) * 1992-10-06 1994-04-26 Merck & Co., Inc. Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith
RU2040932C1 (ru) * 1993-12-17 1995-08-09 Крестьянское хозяйство "Агрофирма Дижа" Препарат, влияющий на тканевой обмен и применение штамма гриба fusarium sambucinum fuckel var ossicolum (berk.et curf) bilai для его получения
CN1072649C (zh) * 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
JP3479796B2 (ja) * 1995-09-13 2003-12-15 武田薬品工業株式会社 ベンゾオキサゼピン化合物
US6537987B1 (en) * 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
PL360243A1 (en) * 2000-06-23 2004-09-06 Takeda Chemical Industries,Ltd Benzoxazepinones and their use as squalene synthase inhibitors
US20040063750A1 (en) * 2000-11-09 2004-04-01 Tomoyuki Nishimoto High-density lipoprotein-cholesterol level elevating agent
DE50100901D1 (de) * 2001-04-12 2003-12-11 Vesifact Ag Baar Coenzym Q10 enthaltende Mikroemulsion-Prekonzentrate und Mikroemulsionen
CA2451163A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Agent for preventing or treating organ functional disorders and order dysfunction
CA2513170A1 (en) * 2003-01-17 2004-08-05 Takeda Pharmaceutical Company Limited Skeletal muscle protecting agent

Also Published As

Publication number Publication date
MX2007014730A (es) 2008-02-15
AU2006253255A1 (en) 2006-12-07
IL187207A0 (en) 2008-06-05
PE20070603A1 (es) 2007-06-22
MA29531B1 (fr) 2008-06-02
RU2007149337A (ru) 2009-07-10
BRPI0610484A2 (pt) 2017-01-31
WO2006129859A2 (en) 2006-12-07
TW200714280A (en) 2007-04-16
CA2609784A1 (en) 2006-12-07
AR054368A1 (es) 2007-06-20
CR9521A (es) 2008-02-22
KR20080012916A (ko) 2008-02-12
WO2006129859A3 (en) 2007-04-19
JP2008542191A (ja) 2008-11-27
EP1962832A2 (en) 2008-09-03
US20090209510A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
NO20076566L (no) Ny fremgangsmate for behandling av hyperlipidemi
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
NO20091544L (no) Sammensetninger av CHK1 inhibitorer
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2007092622A3 (en) Compositions and methods for treating bone
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
WO2008127275A3 (en) Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
NO20081042L (no) PPAR aktive forbindelser
TW200638950A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
SG155163A1 (en) Pharmacokinetically improved compounds
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
WO2006089087A9 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
NO20082075L (no) Anti-hyperkolesterolemiske forbindelser
WO2006121719A3 (en) Soluble epoxide hydrolase inhibitors and methods of using same
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
EP1633311A4 (en) COMPOSITIONS AND METHODS FOR MODULATING S-NITROSOGLUTATHION REDUCTASE
BRPI0509926A (pt) imidazóis
NO20075321L (no) Fremgangsmate for bronnbehandling og konstruksjon
ATE512967T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen
BRPI0507859A (pt) uso dos inibidores da colinesterase
WO2006117761A3 (en) Magnesium salts of hmg-coa reductase inhibitors
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application